David Eberhard

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone…

Journal of Clinical Oncology · 2005 · First of 19 authors · 1,234 citations

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine…

Journal of Clinical Oncology · 2005 · 444 citations